Regeneron, Adicet in cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Adicet Bio Inc. (Menlo Park, Calif) partnered to develop "off-the-shelf" chimeric antigen receptor (CAR) and T cell receptor (TCR) products.

The companies said they will collaborate to identify and validate targets for use in the immunotherapy program, and will seek targeting approaches that may provide greater efficacy against solid tumors than existing immunotherapies have shown. ...